Literature DB >> 24550414

Extended progression-free survival in two patients with alveolar soft part sarcoma exposed to tivantinib.

John M Goldberg1, Tara Gavcovich2, Gaurav Saigal2, Jonathan W Goldman3, Lee S Rosen3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24550414      PMCID： PMC4876351          DOI： 10.1200/JCO.2013.48.7462

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  10 in total

1.  Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma.

Authors:  Amedeo A Azizi; Christine Haberler; Thomas Czech; Astrid Gupper; Daniela Prayer; Helene Breitschopf; Till Acker; Irene Slavc
Journal:  Lancet Oncol       Date:  2006-06       Impact factor: 41.316

Review 2.  Targeting angiogenesis for the treatment of sarcoma.

Authors:  Lakshmi Balasubramanian; Andrew M Evens
Journal:  Curr Opin Oncol       Date:  2006-07       Impact factor: 3.645

3.  The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25.

Authors:  M Ladanyi; M Y Lui; C R Antonescu; A Krause-Boehm; A Meindl; P Argani; J H Healey; T Ueda; H Yoshikawa; A Meloni-Ehrig; P H Sorensen; F Mertens; N Mandahl; H van den Berghe; R Sciot; P Dal Cin; J Bridge
Journal:  Oncogene       Date:  2001-01-04       Impact factor: 9.867

4.  Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial.

Authors:  Andrew J Wagner; John M Goldberg; Steven G Dubois; Edwin Choy; Lee Rosen; Alberto Pappo; James Geller; Ian Judson; David Hogg; Neil Senzer; Ian J Davis; Feng Chai; Carol Waghorne; Brian Schwartz; George D Demetri
Journal:  Cancer       Date:  2012-05-17       Impact factor: 6.860

5.  HGF regulates VEGF expression via the c-Met receptor downstream pathways, PI3K/Akt, MAPK and STAT3, in CT26 murine cells.

Authors:  Atsushi Matsumura; Takeshi Kubota; Hiroaki Taiyoh; Hitoshi Fujiwara; Kazuma Okamoto; Daisuke Ichikawa; Atsushi Shiozaki; Shuhei Komatsu; Masayoshi Nakanishi; Yoshiaki Kuriu; Yasutoshi Murayama; Hisashi Ikoma; Toshiya Ochiai; Yukihito Kokuba; Takahiro Nakamura; Kunio Matsumoto; Eigo Otsuji
Journal:  Int J Oncol       Date:  2012-12-06       Impact factor: 5.650

6.  Alveolar soft part sarcoma in Japan: multi-institutional study of 57 patients from the Japanese Musculoskeletal Oncology Group.

Authors:  Akira Ogose; Yasuo Yazawa; Takafumi Ueda; Tetsuo Hotta; Hiroyuki Kawashima; Hiroshi Hatano; Tetsuro Morita
Journal:  Oncology       Date:  2003       Impact factor: 2.935

7.  Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation.

Authors:  Yu-Wen Zhang; Yanli Su; Olga V Volpert; George F Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-10       Impact factor: 11.205

8.  TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition.

Authors:  Masumi Tsuda; Ian J Davis; Pedram Argani; Neerav Shukla; Gael G McGill; Makoto Nagai; Tsuyoshi Saito; Marick Laé; David E Fisher; Marc Ladanyi
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

Review 9.  Chemotherapy in alveolar soft part sarcomas. What do we know?

Authors:  P Reichardt; T Lindner; D Pink; P C Thuss-Patience; A Kretzschmar; B Dörken
Journal:  Eur J Cancer       Date:  2003-07       Impact factor: 9.162

10.  Expression of MET in alveolar soft part sarcoma.

Authors:  Hyun Jung Jun; Jeeyun Lee; Do Hyoung Lim; Joon Oh Park; Geunghwan Ahn; Sung Wook Seo; Ki-Sun Sung; Do Hoon Lim; Keon Hee Yoo; Yoon-La Choi
Journal:  Med Oncol       Date:  2009-05-27       Impact factor: 3.064
  10 in total
  8 in total

1.  Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines.

Authors:  John M Goldberg; David E Fisher; George D Demetri; Donna Neuberg; Stephen A Allsop; Catia Fonseca; Yukoh Nakazaki; David Nemer; Chandrajit P Raut; Suzanne George; Jeffrey A Morgan; Andrew J Wagner; Gordon J Freeman; Jerome Ritz; Cecilia Lezcano; Martin Mihm; Christine Canning; F Stephen Hodi; Glenn Dranoff
Journal:  Clin Cancer Res       Date:  2015-03-24       Impact factor: 12.531

Review 2.  The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer.

Authors:  Kim Moran-Jones
Journal:  Mol Diagn Ther       Date:  2016-06       Impact factor: 4.074

3.  Establishment and characterization of NCC-ASPS1-C1: a novel patient-derived cell line of alveolar soft-part sarcoma.

Authors:  Yuki Yoshimatsu; Rei Noguchi; Ryuto Tsuchiya; Akane Sei; Jun Sugaya; Suguru Fukushima; Akihiko Yoshida; Akira Kawai; Tadashi Kondo
Journal:  Hum Cell       Date:  2020-07-10       Impact factor: 4.174

Review 4.  The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets.

Authors:  Laura Rocchi; Stefano Caraffi; Roberto Perris; Domenica Mangieri
Journal:  Biosci Rep       Date:  2014-11-04       Impact factor: 3.840

5.  Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma.

Authors:  Kenta Mukaihara; Yu Tanabe; Daisuke Kubota; Keisuke Akaike; Takuo Hayashi; Kaoru Mogushi; Masaki Hosoya; Shingo Sato; Eisuke Kobayashi; Taketo Okubo; Youngji Kim; Shinji Kohsaka; Tsuyoshi Saito; Kazuo Kaneko; Yoshiyuki Suehara
Journal:  PLoS One       Date:  2017-09-25       Impact factor: 3.240

6.  Frequent expression of human leukocyte antigen class I and the status of intratumoral immune cells in alveolar soft part sarcoma.

Authors:  Akira Ogose; Hiroyuki Kawashima; Tetsuo Hotta; Takashi Ariizumi; Tetsuro Yamagishi; Naoki Oike; Taro Sasaki; Hiroshi Hatano; Hajime Umezu; Naoto Endo
Journal:  Oncol Lett       Date:  2017-02-08       Impact factor: 2.967

Review 7.  Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment.

Authors:  Yilong Zhang; Rajul K Jain; Min Zhu
Journal:  Biomedicines       Date:  2015-03-19

8.  Tivantinib Hampers the Proliferation of Glioblastoma Cells via PI3K/Akt/Mammalian Target of Rapamycin (mTOR) Signaling.

Authors:  Yukun Wu; Zhizhang Li; Lijuan Zhang; Guiyang Liu
Journal:  Med Sci Monit       Date:  2019-10-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.